Fast Market Research

EpiCast Report: Parkinson's Disease - Epidemiology Forecast to 2022 - New Study Released

Fast Market Research recommends "EpiCast Report: Parkinson's Disease - Epidemiology Forecast to 2022" from GlobalData, now available

 
Repost This

Boston, MA -- (SBWIRE) -- 12/23/2013 -- Parkinson's disease is the second most common chronic progressive neurodegenerative disorder in the elderly after Alzheimer's disease, affecting 1%-2% of individuals ages =65 years worldwide.
Parkinson's disease is associated with motor symptoms involving bradykinesia, rest tremor, rigidity, and postural disturbances, in addition to non-motor symptoms including hyposmia, rapid eye movements, sleep behavior disorder, and depression. Age, genetics, sex, and environmental exposure increase the risk of developing Parkinson's disease. Conditions such as depression and anxiety have been identified as comorbidities in Parkinson's disease.

View Full Report Details and Table of Contents

In 2012, there were 2,179,414 diagnosed cases of Parkinson's disease in the 8MM. By 2022, GlobalData epidemiologists forecast there will be 2,893,575 diagnosed cases of Parkinson's disease in the 8MM. The US will have the highest number of cases in 2022, followed by Brazil and Japan.

The 8MM will be important markets for Parkinson's disease during the next 10 years because these countries have a growing older population. Japan's current and growing elderly population is the strongest contributor and key driver for increases in Parkinson's disease prevalent cases in Japan. With greater advances in accurately detecting and diagnosing Parkinson's disease in addition to creating a globally and nationally recognized Parkinson's disease registry, we can help further improve our epidemiological understanding of this disorder.

Scope

- The Parkinson's disease EpiCast Report provides an overview of the risk factors and comorbidities for Parkinson's disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Brazil). It includes a 10-year epidemiological forecast of diagnosed prevalent cases of Parkinson's disease segmented by sex and age (ages 65-85+ years).
- The Parkinson's disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global Parkinson's disease market.
- Quantify patient populations in the global Parkinson's disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Parkinson's disease therapeutics in each of the markets covered.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Alzheimer's Disease - Epidemiology Forecast to 2022
- EpiCast Report: Crohn's Disease Epidemiology Forecast to 2022
- EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2022
- EpiCast Report: Meningococcal Disease - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022
- EpiCast Report: Nonalcoholic Steatohepatitis - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
- EpiCast Report: Hemophilia - Epidemiology Forecast to 2022